<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>136(2)</volume><submitter>Deng Z</submitter><journal>Chinese medical journal</journal><pagination>230-232</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10106261</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.</pubmed_title><pmcid>PMC10106261</pmcid><pubmed_authors>Cai S</pubmed_authors><pubmed_authors>Wen Z</pubmed_authors><pubmed_authors>Fu X</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Wu P</pubmed_authors><pubmed_authors>Huang M</pubmed_authors><pubmed_authors>C-BIOPRED Consortium</pubmed_authors><pubmed_authors>Chung KF</pubmed_authors><pubmed_authors>Huang K</pubmed_authors><pubmed_authors>Wei X</pubmed_authors><pubmed_authors>Wang G</pubmed_authors><pubmed_authors>Han Z</pubmed_authors><pubmed_authors>Ou C</pubmed_authors><pubmed_authors>Shen H</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Tang H</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Qiu Z</pubmed_authors><pubmed_authors>Jiang W</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Deng Z</pubmed_authors><pubmed_authors>Jin M</pubmed_authors><pubmed_authors>Kang J</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>He B</pubmed_authors><pubmed_authors>Tang Y</pubmed_authors><pubmed_authors>Chen P</pubmed_authors><pubmed_authors>Gu W</pubmed_authors><pubmed_authors>Wei C</pubmed_authors><pubmed_authors>Xie L</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Zhong N</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Zhu L</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Shi G</pubmed_authors><pubmed_authors>Lin J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.</name><description/><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-26T04:59:02.521Z</modification><creation>2025-04-06T11:22:59.142Z</creation></dates><accession>S-EPMC10106261</accession><cross_references><pubmed>36752798</pubmed><doi>10.1097/CM9.0000000000002556</doi></cross_references></HashMap>